Greencore Group shares rise as interims signal positive momentum

Greencore Group shares rose 6.25% to 238p after the prepared-foods group reported FY25 revenue up 7.7% to £1.95bn and adjusted operating profit up 28.9% to £125.7m, with free cash flow of £120.5m and net debt reduced to £70.1m. The company signed a binding agreement to sell its Bristol chilled soups and sauces site to Compleat Food Group — a disposal the Competition and Markets Authority has given in-principle acceptance to as the remedy to avoid a Phase 2 probe — advancing its recommended acquisition of Bakkavor. Greencore said momentum has continued into FY26 and still expects the Bakkavor transaction to complete in early 2026, subject to final CMA approval and court sanction, which would create scale and synergies for the combined business.

Analysis

Greencore reported FY25 revenue of £1.95bn, up 7.7% year-over-year, with adjusted operating profit rising 28.9% to £125.7m; management attributed the outperformance to new business wins, underlying volume growth and improved operational efficiency. The company generated free cash flow of £120.5m and reduced net debt to £70.1m, strengthening its balance sheet ahead of a large strategic transaction. Shares responded positively, trading up 6.25% at 238p, consistent with a moderately positive market tone.

Greencore has signed a binding agreement to sell its Bristol chilled soups and sauces site to Compleat Food Group, and the Competition and Markets Authority has given in-principle acceptance of that disposal as the proposed remedy to avoid a Phase 2 investigation. Management continues to expect completion of the recommended acquisition of Bakkavor in early 2026 subject to final CMA approval and court sanction, a sequence that is the principal near-term execution and regulatory risk.

The combination of stronger profitability, solid cash generation and lower leverage materially improves Greencore's capacity to fund the Bakkavor deal and capture projected synergies, but outcomes remain conditional on regulatory sign-off and court processes. Investors should weigh upside from scale and cost synergies against deal execution risk and potential further remedy requirements that could alter pro forma economics.

Key Decisions for Investors

• Consider initiating or modestly increasing exposure on a measured basis given the stronger FY25 fundamentals and reduced net debt, but size positions to reflect the binary regulatory completion risk
• Treat final CMA approval and court sanction as primary near-term catalysts; set price and news alerts to re-evaluate positions immediately after those milestones
• Use disciplined hedges or position limits to protect against deal failure or additional remedy outcomes that would dilute expected synergies
• Reassess valuation and capital allocation once full pro forma metrics and integration/synergy targets for the combined Greencore-Bakkavor entity are published
• Consider taking partial profits after the recent 6.25% share rally to de-risk near-term exposure while retaining upside to deal completion